- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00764790
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
Visão geral do estudo
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35244
- GSK Investigational Site
-
Birmingham, Alabama, Estados Unidos, 35205
- GSK Investigational Site
-
Dothan, Alabama, Estados Unidos, 36305
- GSK Investigational Site
-
-
Arkansas
-
Benton, Arkansas, Estados Unidos, 72019
- GSK Investigational Site
-
Conway, Arkansas, Estados Unidos, 72034
- GSK Investigational Site
-
Fayetteville, Arkansas, Estados Unidos, 72703
- GSK Investigational Site
-
Jonesboro, Arkansas, Estados Unidos, 72401
- GSK Investigational Site
-
Little Rock, Arkansas, Estados Unidos, 72205
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, Estados Unidos, 92647
- GSK Investigational Site
-
Long Beach, California, Estados Unidos, 90806
- GSK Investigational Site
-
Paramount, California, Estados Unidos, 90723
- GSK Investigational Site
-
Sacramento, California, Estados Unidos, 95816
- GSK Investigational Site
-
San Francisco, California, Estados Unidos, 94102
- GSK Investigational Site
-
West Covina, California, Estados Unidos, 91790
- GSK Investigational Site
-
-
Colorado
-
Longmont, Colorado, Estados Unidos, 80501
- GSK Investigational Site
-
-
Connecticut
-
Norwich, Connecticut, Estados Unidos, 06360
- GSK Investigational Site
-
-
Idaho
-
Nampa, Idaho, Estados Unidos, 83686
- GSK Investigational Site
-
-
Illinois
-
DeKalb, Illinois, Estados Unidos, 60115
- GSK Investigational Site
-
-
Indiana
-
New Albany, Indiana, Estados Unidos, 47150
- GSK Investigational Site
-
-
Kansas
-
Arkansas City, Kansas, Estados Unidos, 67005
- GSK Investigational Site
-
Newton, Kansas, Estados Unidos, 67114
- GSK Investigational Site
-
Wichita, Kansas, Estados Unidos, 67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown, Kentucky, Estados Unidos, 40004
- GSK Investigational Site
-
Louisville, Kentucky, Estados Unidos, 40207
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, Estados Unidos, 71111
- GSK Investigational Site
-
Metairie, Louisiana, Estados Unidos, 70006
- GSK Investigational Site
-
-
Michigan
-
Stevensville, Michigan, Estados Unidos, 49127
- GSK Investigational Site
-
-
Minnesota
-
Saint Paul, Minnesota, Estados Unidos, 55108
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, Estados Unidos, 63141
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68134
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Estados Unidos, 89015
- GSK Investigational Site
-
-
New York
-
Cortland, New York, Estados Unidos, 13045
- GSK Investigational Site
-
-
North Carolina
-
Boone, North Carolina, Estados Unidos, 28607
- GSK Investigational Site
-
Cary, North Carolina, Estados Unidos, 27518
- GSK Investigational Site
-
Raleigh, North Carolina, Estados Unidos, 27609
- GSK Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58103
- GSK Investigational Site
-
-
Ohio
-
Austintown, Ohio, Estados Unidos, 44515
- GSK Investigational Site
-
Cincinnati, Ohio, Estados Unidos, 45245
- GSK Investigational Site
-
Cleveland, Ohio, Estados Unidos, 44121
- GSK Investigational Site
-
Dayton, Ohio, Estados Unidos, 45406
- GSK Investigational Site
-
-
Oregon
-
Gresham, Oregon, Estados Unidos, 97030
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, Estados Unidos, 16505
- GSK Investigational Site
-
Greenville, Pennsylvania, Estados Unidos, 16125
- GSK Investigational Site
-
Latrobe, Pennsylvania, Estados Unidos, 15650
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Estados Unidos, 15236
- GSK Investigational Site
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- GSK Investigational Site
-
Wexford, Pennsylvania, Estados Unidos, 15090
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29406
- GSK Investigational Site
-
-
Tennessee
-
Clarksville, Tennessee, Estados Unidos, 37043
- GSK Investigational Site
-
Jackson, Tennessee, Estados Unidos, 38305
- GSK Investigational Site
-
Kingsport, Tennessee, Estados Unidos, 37660
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- GSK Investigational Site
-
Fort Worth, Texas, Estados Unidos, 76135
- GSK Investigational Site
-
Houston, Texas, Estados Unidos, 77055
- GSK Investigational Site
-
San Angelo, Texas, Estados Unidos, 76904
- GSK Investigational Site
-
-
Utah
-
Bountiful, Utah, Estados Unidos, 84010
- GSK Investigational Site
-
Layton, Utah, Estados Unidos, 84041
- GSK Investigational Site
-
Murray, Utah, Estados Unidos, 84107
- GSK Investigational Site
-
Provo, Utah, Estados Unidos, 84604
- GSK Investigational Site
-
Roy, Utah, Estados Unidos, 84067
- GSK Investigational Site
-
South Jordan, Utah, Estados Unidos, 84095
- GSK Investigational Site
-
-
Virginia
-
Burke, Virginia, Estados Unidos, 22015
- GSK Investigational Site
-
-
-
-
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Mexico, México, 6720
- GSK Investigational Site
-
Mexico city, México, 04530
- GSK Investigational Site
-
-
-
-
-
Bangkok, Tailândia, 10400
- GSK Investigational Site
-
-
-
-
-
Taipei, Taiwan, 104
- GSK Investigational Site
-
Taipei, Taiwan
- GSK Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
- Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject's parent/guardian.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
- History of hypersensitivity to any vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- Acute disease at the time of enrolment.
- History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
- Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Fluarix Dose A Group
Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
Experimental: Fluarix Dose B Group
Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
Comparador Ativo: Fluzone Group
Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Prazo: Day 0 (PRE), Day 28 or Day 56 (POST)
|
GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
Number of Subjects Who Seroconverted
Prazo: Day 28 or Day 56
|
Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of Seroprotected Subjects
Prazo: Day 0 (PRE), Day 28 or Day 56 (POST)
|
A seroprotected subject is a subject with a serum anti-HA titer ≥ 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
Seroconversion Factor
Prazo: Day 28 or Day 56
|
Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Number of Subjects Reporting Solicited Local Symptoms
Prazo: During a 4-day follow-up period after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During a 4-day follow-up period after vaccination
|
Number of Subjects Reporting Solicited General Symptoms
Prazo: During a 4-day follow-up period after vaccination
|
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
|
During a 4-day follow-up period after vaccination
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Prazo: During a 28-day follow-up period after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
|
During a 28-day follow-up period after vaccination
|
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Prazo: During the entire study (Day 0 until Month 6)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6)
|
Number of Subjects Reporting Rare Serious Events
Prazo: During the entire study (Day 0 until Month 6)
|
Rare serious events have an occurrence rate of 1/300 (0.3%).
|
During the entire study (Day 0 until Month 6)
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Li-Kim-Moy J, Wood N, Jones C, Macartney K, Booy R. Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children. Pediatr Infect Dis J. 2018 Oct;37(10):971-975. doi: 10.1097/INF.0000000000001949.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 111751
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Dados/documentos do estudo
-
Especificação do conjunto de dados
Identificador de informação: 111751Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Consentimento Informado
Identificador de informação: 111751Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Plano de Análise Estatística
Identificador de informação: 111751Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Relato de Caso Anotado
Identificador de informação: 111751Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Relatório de Estudo Clínico
Identificador de informação: 111751Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de dados de participantes individuais
Identificador de informação: 111751Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudo
Identificador de informação: 111751Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Fluarix
-
GlaxoSmithKlineConcluído
-
GlaxoSmithKlineConcluído
-
GlaxoSmithKlineConcluído
-
GlaxoSmithKlineConcluído
-
National Institute of Allergy and Infectious Diseases...Concluído
-
GlaxoSmithKlineConcluído
-
GlaxoSmithKlineConcluído
-
Emory UniversityRescindido
-
GlaxoSmithKlineConcluídoGripeEstados Unidos, Alemanha, Polônia, Holanda
-
Public Health EnglandRoyal Free and University College Medical SchoolConcluído